AN ACT relating to undesignated glucagon.
HB 263 likely permits broader public access to undesignated glucagon emergency medication for hypoglycemia treatment without individual prescriptions, similar to naloxone policies.
HB 263 likely permits broader public access to undesignated glucagon emergency medication for hypoglycemia treatment without individual prescriptions, similar to naloxone policies.
HB 263 addresses the regulation and distribution of undesignated glucagon—a medication used to treat severe hypoglycemia (dangerously low blood sugar). The bill likely expands access to glucagon by allowing it to be dispensed or administered without being prescribed for a specific individual, similar to how many states now permit public access to naloxone (Narcan) for opioid overdoses.
Severe hypoglycemia is a medical emergency that can cause seizures, loss of consciousness, or death. Making glucagon more readily available in public spaces, workplaces, and schools—without requiring a prescription written for a specific person—could save lives, particularly for people with diabetes who may experience emergencies away from medical supervision. This aligns with public health trends toward broader emergency medication access.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.